RESCHEDULED: Real-World CAR-T Data Update
Myeloma patients and their loved ones have been learning about the novel CAR-T therapies that are significantly improving myeloma care. A lot of the information we have comes from clinical trials. What are we learning in the clinic about CAR-T, including how older patients are responding, what long-term side effects look like, and more?
Come with your questions and get ready to learn with us!
Audrey introduces the agenda of the event and featured speaker Sham Mailankody, MBBS.
Dr. Sham Mailankody discusses how real-world data is informing us about novel CAR-T therapies.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Sham Mailankody, MBBS
I am a medical oncologist specializing in the care of people with multiple myeloma and related plasma cell disorders. With my colleagues at Memorial Sloan Kettering Cancer Center (MSK), I am focused on identifying optimal treatment strategies for people with these disorders. My research focuses on the development of novel immune and cellular therapies, including chimeric antigen receptor (CAR) T cell therapies, for patients with myeloma. I also serve as the Clinical Director of the Cellular Therapy Service and the Research Director of the Myeloma Service at MSK.